Integral Health Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Integral Health Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-225,000	Closed	-$1.82M	–	76
2023 Q1	$1.82M	Sell	225,000 -145,000	-39%	-$1.84M	0.37%	66
2022 Q4	$5.83M	Buy	370,000 +30,000	+9%	+$483K	1.22%	32
2022 Q3	$5.35M	Buy	340,000 +54,029	+19%	+$851K	1.04%	40
2022 Q2	$3.99M	Buy	285,971 +47,971	+20%	+$672K	0.82%	43
2022 Q1	$4.1M	Buy	238,000 +38,000	+19%	+$518K	1.07%	35
2021 Q4	$2.91M	Buy	200,000 +15,000	+8%	+$227K	0.8%	40
2021 Q3	$3.33M	Buy	185,000 +10,000	+6%	+$160K	0.96%	46
2021 Q2	$3.07M	Buy	+175,000	New	+$3.98M	0.85%	43

Other funds holding ACRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Integral Health Asset Management's ACRS Position: Q2 2023 in Review

Integral Health Asset Management sold out of Aclaris Therapeutics (ACRS) in Q2 2023, closing a stake of 225,000 shares — an estimated $1.82M sold.

Integral Health Asset Management first reported a position in ACRS in Q2 2021 and held it in 8 quarters. The position peaked at $5.83M in Q4 2022. 133 funds tracked by Wall St. Rank hold ACRS as of Q2 2023.

Integral Health Asset Management reported no remaining Aclaris Therapeutics position as of Q2 2023 after selling out during the quarter.
Integral Health Asset Management sold 225,000 Aclaris Therapeutics shares in Q2 2023, an estimated $1.82M.
Integral Health Asset Management first reported a position in Aclaris Therapeutics in Q2 2021 and held it in 8 quarters.
Integral Health Asset Management's Aclaris Therapeutics position peaked at $5.83M in Q4 2022.
133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2023.

Based on Integral Health Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.